Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.415 USD | +0.71% | -5.08% | -87.12% |
Apr. 17 | Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating | MT |
Apr. 16 | Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.12% | 77.17M | |
+26.82% | 661B | |
+27.40% | 566B | |
-6.37% | 352B | |
+20.39% | 332B | |
+2.92% | 283B | |
+13.96% | 231B | |
+5.17% | 200B | |
-9.08% | 195B | |
-5.00% | 145B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- RBC Lifts Price Target on Marinus Pharmaceuticals to $21 From $20, Keeps Outperform Rating, Speculative Risk Qualifier